(VIANEWS) – SMARTCRAFT (SMCRT.OL), TOMRA SYSTEMS (TOM.OL), MEDISTIM (MEDI.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SMARTCRAFT (SMCRT.OL)
23.7% sales growth and 10.68% return on equity
SmartCraft ASA provides software solutions to the construction industry in Norway, Sweden, and Finland. The company offers Cordel; Bygglet, a SaaS born in the cloud solution; EL-VIS, a solution for electricians; and Congrid, a cloud-based tool for project management in construction companies. It also provides HomeRun, a digital tool for construction, project communication, document, and procurement management; Kvalitetskontroll, a cloud-based project management solution and quality assurance platform for construction companies; El-verdi, a digital sales tool for electricians; and ELinn, a cloud based solution for electricians to handle project management services. The company was founded in 1987 and is headquartered in Hønefoss, Norway.
Earnings Per Share
As for profitability, SMARTCRAFT has a trailing twelve months EPS of kr0.48.
PE Ratio
SMARTCRAFT has a trailing twelve months price to earnings ratio of 41.88. Meaning, the purchaser of the share is investing kr41.88 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.68%.
More news about SMARTCRAFT.
2. TOMRA SYSTEMS (TOM.OL)
17.6% sales growth and 15.76% return on equity
Tomra Systems ASA provides sensor-based solutions for optimal resource productivity worldwide. It operates through three segments: TOMRA Collection, TOMRA Recycling, and TOMRA Food. The TOMRA Collection segment engages in the development, production, sale, and service of reverse vending machines and related data management systems. This segment is also involved in picking up, transporting, and processing empty beverage containers on behalf of beverage producers/fillers. The TOMRA Recycling segment engages in the development, production, sale, and service of sorting and processing technology for waste management companies or plant builders. This segment offers sorting systems for waste and metal material streams; and ore sorting systems for mining companies. The TOMRA Food segment is involved in the development, production, sale, and service of sorting and processing technology, including sensor-based sorting solutions and integrated post-harvest solutions to detect and eject unwanted materials from manufacturing and processing lines for fresh and processed food industries. The company was founded in 1972 and is headquartered in Asker, Norway.
Earnings Per Share
As for profitability, TOMRA SYSTEMS has a trailing twelve months EPS of kr3.53.
PE Ratio
TOMRA SYSTEMS has a trailing twelve months price to earnings ratio of 48.81. Meaning, the purchaser of the share is investing kr48.81 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.76%.
Sales Growth
TOMRA SYSTEMS’s sales growth is 25.6% for the current quarter and 17.6% for the next.
More news about TOMRA SYSTEMS.
3. MEDISTIM (MEDI.OL)
16.7% sales growth and 31.89% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.39.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 41.16. Meaning, the purchaser of the share is investing kr41.16 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Moving Average
MEDISTIM’s worth is below its 50-day moving average of kr271.10 and above its 200-day moving average of kr241.57.
Sales Growth
MEDISTIM’s sales growth is 15.7% for the present quarter and 16.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.7%.
More news about MEDISTIM.
4. OENEO (SBT.PA)
6.7% sales growth and 12.71% return on equity
Oeneo SA operates in the wine industry worldwide. The company manufactures and sale of cork closures. It also provides solutions in wine making and spirits. Oeneo SA is headquartered in Bordeaux, France. Oeneo SA is a subsidiary of Caspar SAS.
Earnings Per Share
As for profitability, OENEO has a trailing twelve months EPS of €0.63.
PE Ratio
OENEO has a trailing twelve months price to earnings ratio of 22.7. Meaning, the purchaser of the share is investing €22.7 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Moving Average
OENEO’s worth is above its 50-day moving average of €14.02 and below its 200-day moving average of €14.42.
More news about OENEO.
5. IMCD (IMCD.AS)
6.5% sales growth and 19.97% return on equity
IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company offers bioactives, biocides, chelates, functional additives, rheology modifiers, silicones, solubilisers, and solvents; active pharmaceutical, agrochemicals, biopharma, excipients and formulation, nutraceuticals, and regulated synthesis; actives, UV sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, elastomers, humectants, waxes, film formers, functional powders, hair styling polymers, hair conditioners, solvents, solubilizers, pigments, pearls, colorants, opacifiers, pearlisers, preservatives, antioxidants, additives, fragrances, and essential oils; and resins and binders, additives, functional fillers, and specialty solvents. It also provides taste, texture, nutrition, and function; base oil, fuel addictive, lubricants addictive, lubricants finished fluids, solvents, degreasers and fuel, compounds, and upstream, midstream and downstream oil, gas and energy; bio-based chemicals, binders, corrosion inhibitors, catalysts, intermediates, monomers, organic building blocks, processing aids, reactive diluents, solvents, and surfactants. IMCD N.V. was founded in 1995 and is headquartered in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, IMCD has a trailing twelve months EPS of €5.49.
PE Ratio
IMCD has a trailing twelve months price to earnings ratio of 26.32. Meaning, the purchaser of the share is investing €26.32 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.97%.
Moving Average
IMCD’s value is above its 50-day moving average of €142.27 and above its 200-day moving average of €139.73.
More news about IMCD.
